Pathophysiological roles for IL-18 in inflammatory arthritis

Bibliography

• IMLER JL, HOFFMANN JA: Toll receptors in Drosophila: a family of molecules regulating development and immunity. Curr. Top. Microbial. brununol. (2002) 270:63–79.
   PubMed Web of Science ®Google Scholar
• HOFFMANN JA, REICHHART JM: Drosophila innate immunity: an evolutionary perspective. Nat. Irrununol. (2002) 3:121–126.
   Google Scholar
• JANEWAY CA Jr, MEDZHITOV R: Innate immune recognition. AMU. Rev Inununol. (2002) 20:197–216.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of innate immunity.
   Google Scholar
• MEDZHITOV R, JANEWAY CA Jr: Innate immunity: the virtues of a nonclonal system of recognition. Cell (1997) 91:295–298.
   PubMed Web of Science ®Google Scholar
• O'NEILL LA, DINARELLO CA: The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. brununol. Today (2000) 21:206–209.
   PubMed Web of Science ®Google Scholar
• AKIRA S, TAKEDA K, KAISHO T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. brununol. (2001) 2:675–680.
   PubMed Web of Science ®Google Scholar
• TAKEDA K, KAISHO T, AKIRA S: Toll-like receptors. AMU. Rev Inununol. (2003) 21:335–376.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of TLRs.
   Google Scholar
• OKAMURA H, TSUTSUI H, KOMATSU T et al.: Cloning of a new cytokine that induces IFN-y production by T cells. Nature (1995) 378:88–91.
   PubMed Web of Science ®Google Scholar
• •Original report of the discovery of IL-18.
   Google Scholar
• KIM J, OCHOA MT, KRUTZIK SR et al:Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. brununol. (2002) 169:1535–1541.
   Google Scholar
• OKAMURA H, TSUTSUI H, KASHIWAMURA S, YOSHIMOTO T, NAKANISHI K: Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv. Inununol. (1998) 70:281–312.
   PubMed Web of Science ®Google Scholar
• OKAMURA H, KASHIWAMURA S, TSUTSUI H, YOSHIMOTO T, NAKANISHI K: Regulation of interferon-y production by IL-12 and IL-18. Curr. °pia brununol. (1998) 10:259–264.
   PubMed Web of Science ®Google Scholar
• FANTUZZI G, DINARELLO CA: Interleukin-18 and interleukin-1[3: two cytokine substrates for ICE (caspase-1). J. aim brununol. (1999) 19:1–11.
   Google Scholar
• DINARELLO CA: Interleukin-113, interleukin-18, and the interleukin-lp converting enzyme. Ann. NY Acad. Sri. (1998) 856:1–11.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA, FANTUZZI G: Interleukin-18 and host defense against infection. J. Infect. Di t (2003) 187:S370–S384.
   Google Scholar
• TSUTSUI H, MATSUI K, OKAMURA H, NAKANISHI K: Pathophysiological roles of interleukin-18 for inflammatory liver diseases. brununol. Rev (2000) 174:192–209.
   Google Scholar
• TSUTSUI H, YOSHIMOTO T, OKAMURAH, AKIRA S, NAKANISHI K: IL-18 and IL-18 receptor knockout mouse. In: Cytokine Knockouts (2nd edit). Fantuzzi G (Ed.), Humana Press, Totowa, NJ (2003):303–322.
   Google Scholar
• ••A thorough review of thepathophysiological importance of endogenous IL-18 and the IL–18R.
   Google Scholar
• ISUTSUI H, ADACHI K, SEKI E, NAKANISHI K: Cytokine-induced inflammatory liver injuries. Curc Ma. Med. (2003) 3:545–559.
   PubMed Web of Science ®Google Scholar
• NAKANISHI K, YOSHIMOTO T, ISUTSUI H, OKAMURA H: Interleukin-18 regulates both TH1 and TH2 responses. AMU. Rev Immunol (2001) 19:423–474.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of IL-18.
   Google Scholar
• OKAMURA H, LOTZE MT, ISUTSUI H et al.: Interleukin-18 [IL-1F4]. In: The Cytokine Handbook (4th edrt). Thomson AW, Lotze MT (Eds), Academic Press, NY (2003):709–733.
   Google Scholar
• ISUTSUI H, YOSHIMOTO T, OKAMURA H, NAKANISHI K: Interleukin-18. In: Encyclopedia Hormones. Henry HL, Norman AW (Eds), Academic Press, New York (2003). In Press.
   Google Scholar
• •A current review of IL-18.
   Google Scholar
• USHIO S, NAMBA M, OKURA T et al: Cloning of the cDNA for human IFN-y-inducing factor, expression in Escherichia coil, and studies on the biologic activities of the protein. J. konunol. (1996) 156:4274–4279.
   Google Scholar
• BAZAN JF, TIMANS JC, KASTELEIN RA: A newly defined interleukin-1? Nature (1996) 379:591.
   PubMed Web of Science ®Google Scholar
• TONE M, THOMPSON SA, IONE Y, FAIRCHILD PJ, WALDMANN H: Regulation of IL-18 (IFN-y-inducing factor) gene expression. J. Immuna (1997) 159:6156–6163.
   PubMed Web of Science ®Google Scholar
• KIM YM, KANG HS, PAIK SG et al: Roles of IFN consensus sequence binding protein and PU.1 in regulating IL-18 gene expression../. Immunol (1999) 163:2000–2007.
   Google Scholar
• SHACKELFORD R, ADAMS DO, JOHNSON SP: IFN-y and lipopolysaccharide induce DNA binding of transcription factor PU.1 in murine tissue macrophages. J.Immunol. (1995) 154:1374–1382.
   Google Scholar
• SHARF R, AZRIEL A, LEJBKOWICZ Fet al: Functional domain analysis of interferon consensus sequence binding protein (ICSBP) and its association with interferon regulatory factors. J. Biol. Chem. (1995) 270:13063–13069.
   PubMed Web of Science ®Google Scholar
• STOLL S, MULLER G, KURIMOTO M et al.: Production of IL-18 (IFN-y-inducing factor) messenger RNA and functional protein by murine keratinocytes. Immunol (1997) 159:298–302.
   Web of Science ®Google Scholar
• •Original report of IL-18 in keratinocytes.
   Google Scholar
• SAHA N, MOLD OVAN F, TARDIF G et al.: Interleukin-113-converting enzyme/ caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-lp and interleukin-18. Arthritis Rheum. (1999) 42:1577–1587.
   PubMed Web of Science ®Google Scholar
• •Identification of increased caspase-1 activity in human OA cartilage.
   Google Scholar
• UDAGAWA N, HORWOOD NJ, ELLIOTT J et al.: Interleukin-18 (interferon-y-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-y to inhibit osteoclast formation. Exp. Med. (1997) 185:1005–1012.
   PubMed Web of Science ®Google Scholar
• •Evidence of the inhibitory effect of IL-18 on osteoclast development in vitro.
   Google Scholar
• ISUTSUI H, MATSUI K, KAWADA N et al.: IL-18 accounts for both TNF-a- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. Immunol (1997) 159:3961–3967.
   Web of Science ®Google Scholar
• SEKI E, ISUTSUI H, NAKANO H et al.: Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of Myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1 3. Immunol (2001) 166:2651–2657.
   Web of Science ®Google Scholar
• •Evidence of MyD88-independent IL-18 secretion.
   Google Scholar
• MEE JB, ALAM Y, GROVES RW: Human keratinocytes constitutively produce but not process interleukin-18. Br. J. Dermatol (2000) 143:330–336.
   PubMed Web of Science ®Google Scholar
• NAKANO H, ISUTSUI H, TERADA M et al: Persistent secretion of IL-18 in the skin contributes to IgE response in mice. Int. Immunol (2003) 15:611–621.
   PubMed Web of Science ®Google Scholar
• CAMERON LA, TAHA RA, TSICOPOULOS A et al.: Airway epithelium expresses interleukin-18. Eur. Respic J. (1999) 14:553–559.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI M, NISHIZAKI Y, SANO O et al.: Immunohistochemical and immuno-electron-microscopic detection of interferon-y-inducing factor (interelukin-18) in mouse intestinal epithelial cells. Cell Tissue Res. (1997) 289:499–507.
   PubMed Web of Science ®Google Scholar
• OLEE T, HASHIMOTO S, QUACH J, LOTZE M: IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J. Immunol (1999) 162:1096–1100.
   PubMed Web of Science ®Google Scholar
• •Evaluation of IL-18 as an inducer of catabolic responses in chondrocytes in vitro.
   Google Scholar
• GUY, KUIDA K, ISUTSUI H et al: Activation of interferon-y inducing factor mediated by interleukin-lp convertingenzyme. Science (1997) 275:206–209.
   PubMed Web of Science ®Google Scholar
• •Evidence of requirement of caspase-1 for LPS-induced IL-18 secretion.
   Google Scholar
• GHAYUR T, BANERJEE S, HUGUNIN M et al: Caspase-1 processes IFN-y-inducing factor and regulates LPS-induced IFN-y production. Nature (1997) 386:619–623.
   PubMed Web of Science ®Google Scholar
• •Evidence of the requirement of caspase-1 for LPS-induced IL-18 secretion.
   Google Scholar
• ISUTSUI H, KAYAGAKI N, KUIDA K et al.: Caspase-1 - independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity (1999) 11:359–367.
   PubMed Web of Science ®Google Scholar
• •Evidence of caspase-1-independent IL-18 release.
   Google Scholar
• ALNEMRI ES, LIVINGSTON DJ, NICHOLSON DW et al.: Human ICE/CED-3 protease nomenclature. Cell (1996) 87:171.
   PubMed Web of Science ®Google Scholar
• •Nomenclature of caspases.
   Google Scholar
• EARNSHAW WC, MARTINS LM, KAUFMANN SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. AMU. Rev Biochem. (1999) 68:383–424.
   PubMed Web of Science ®Google Scholar
• LI P, NIJHAWAN K, BUDIHARDJO I et al.: Cytochrome c and dATP-dependent formation of Apaf-l/caspase-9 complex initiates an apoptotic protease cascade. Cell (1997) 91:479–489.
   PubMed Web of Science ®Google Scholar
• THORNBERY NA, BULL HG, CALAYCAY JR et al: A novel heterodimeric cysteine protease is required for interleukin-1i3 processing in monocytes. Nature (1992) 356:768–774.
   PubMed Web of Science ®Google Scholar
• MIWA K, ASANO M, HORAI R et al: Caspase-1 -independent IL-113 release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. (1998) 4:1287–1292.
   PubMed Web of Science ®Google Scholar
• •Evidence of caspase-1-independent IL-1I3 secretion.
   Google Scholar
• SEKI E, TSUTSUI H, TSUJI NM et al.: Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance Listeria monocytogenes in mice. Immunol (2002) 169:3863–3868.
   Web of Science ®Google Scholar
• ADACHI K, TSUTSUI H, KASHIWAMURA S et al.: Plasmodium berghei infection in mice induces liver injury by an IL-12- and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism. Immunol (2001) 167:5928–5934.
   Web of Science ®Google Scholar
• ITOI H, FUJIMORI Y, TSUTSUI H et al: Fas ligand-induced caspase-l-dependent accumulation of interleukin (ID-18 in mice with acute graft-versus-host disease. Blood (2001) 98:235–237.
   PubMed Web of Science ®Google Scholar
• THOMASSEN E, BIRD TA, RENSHAW BR, KENNEDY MK, SIMS JE: Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1RrP1 leads to activation of signaling pathways similar to those used by interleukin-1. Interferon Cytokine Res. (1998) 18:1077–1088.
   PubMed Web of Science ®Google Scholar
• TORIGOE K, USHIO S, OKURA T et al.: Purification and characterization of the human interleukin-18 receptor. Biol. Chem. (1997) 272:25737–24742.
   Web of Science ®Google Scholar
• BORN TL, THOMASSEN E, BIRD TA, SIMS JE: Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. Biol. Chem. (1998) 273:29445–29450.
   Google Scholar
• DEBETS R, TIMANS JC, CHURAKOWA T et al.: IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. Immunol (2000) 165:4950–4956.
   Web of Science ®Google Scholar
• HOSHINO K, TSUTSUI H, KAWAI T et al: Generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. Immunol (1999) 162:5041–5044.
   Web of Science ®Google Scholar
• •Evidence of the requirement of IL-18Ra for IL-18 biology.
   Google Scholar
• NEIGHBORS M, XU X, BARRAT F et al.: A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon y production. 1. Exp. Med. (2001) 194:343–354.
   Google Scholar
• AHN HJ, MARUO S, TOMURA M et al:A mechanism underlying synergy between IL-12 and IFN-y-inducing factor in enhanced production of IFN-y. J.Immunol. (1997) 159:2125–2131.
   PubMed Web of Science ®Google Scholar
• ROBINSON D, SHIBUYA K, MUI A et al: IGIF does not drive TH1 development but synergizes with IL-12 for interferon-y production and activates IRAK and NF-KB. Immunity (1997) 7:571–581.
   PubMed Web of Science ®Google Scholar
• XU D, CHAN WL, LEUNG BP et al.: Selective expression and functions of interleukin 18 receptor on T helper (TH) Type 1 but not TH2 cells. I Exp. Med. (1998) 188:1485–1492.
   PubMed Web of Science ®Google Scholar
• YOSHIMOTO T, TAKEDA K, TANAKA T et al.: IL-12 up-regulates IL-18 receptor expression on T cells, TH1 cells, and B cells: synergism with IL-18 for IFN-y production. Immunol (1998) 161:3400–3407.
   Web of Science ®Google Scholar
• •Evidence of IL-12-induced IL-18 responsiveness in murine TH cells.
   Google Scholar
• TOMINAGA K, YOSHIMOTO T, TORIGOE K et al.: IL-12 synergizes with IL-18 or IL-l3 for IFN-y production from human T cells. Int. Immunol (2000) 12:151–160.
   PubMed Web of Science ®Google Scholar
• HYODO Y, MATSUI K, HAYASHI N et al: IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. Immunol (1999) 162: 1662-1668.
   Google Scholar
• YOSHIMOTO T, MIN B, SUGIMOTO T et al.: Nonredundant roles for CDid-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin-18 treatment of mice. J. Exp. Med. (2003) 197:997–1005.
   PubMed Web of Science ®Google Scholar
• •Requirement of CD id-restrictedNKT cells for IL-18 induction of IgE in mice.
   Google Scholar
• ADACHI O, KAWAI T, TAKEDA K et al: Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 9:143–150.
   PubMed Web of Science ®Google Scholar
• ••Evidence of the requirement of MyD88 forIL-1/IL-18 signallings.
   Google Scholar
• KANAKARAJ P, SCHAFER PH, CAVENDER DE et al.: Interleukin (ID-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. Exp. Med. (1998) 187:2073–2079.
   PubMed Web of Science ®Google Scholar
• NAKANISHI K, YOSHIMOTO T, TSUTSUI H, OKAMURA H: Interleukin-18 is a unique cytokine that stimulates both TH1 and TH2 responses depending on its cytokine milieu. CytokMe Growth Factor Rev (2001) 12:53–72.
   PubMed Web of Science ®Google Scholar
• KAWAI T, ADACHI O, OGAWA T, TAKEDA K, AKIRA S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11:115–122.
   PubMed Web of Science ®Google Scholar
• ••Evidence of the requirement of MyD88 forTLR-mediated signalling.
   Google Scholar
• SUZUKI N, SUZUKI S, DUNCAN GS et al: Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature (2002) 416:750–754.
   PubMed Web of Science ®Google Scholar
• •Evidence of the requirement of IRAK4 for TLR-mediated signalling.
   Google Scholar
• SUZUKI N, CHEN NJ, MILLER DG et al: IRAK-4 is essential for interleukin-18-mediated natural killer and T helper cell Type 1 response. Immunol (2003) 170:4031–4035.
   Google Scholar
• MEDVEDEV AE, LENTSCHAT A, KUHNS DB et al.: Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infection. Exp. Med. (2003) 198:521–531.
   PubMed Web of Science ®Google Scholar
• NOVICK D, KIM SH, FANTUZZI G et al.: Interleukin-18 binding protein: a novel modulator of the TH1 cytokine response. Immunity (1999) 10:127–136.
   PubMed Web of Science ®Google Scholar
• •Identification of IL-18BP.
   Google Scholar
• AIZAWA Y, AKITA K, TANIAI M et al.: Cloning and expression of interleukin-18 binding protein. FEBS Lett. (1999) 445:338–342.
   PubMed Web of Science ®Google Scholar
• •Identification of IL-18BE
   Google Scholar
• REZNIKOV LL, KIM SH, WESTCOTT JY et al.: IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-y. Proc. Natl. Acad. Sri. USA (2000) 97:2174–2179.
   PubMed Web of Science ®Google Scholar
• KIM SH, EISENSTEIN M, REZNIKOV L et al.: Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Li. USA (2000) 97:1190–1195.
   PubMed Web of Science ®Google Scholar
• KIM SH, REZNIKOV LL, STUYT RJ et al: Functional reconstitution and regulation of IL-18 activity by the IL-18R13 chain. I Immunol (2001) 166:148–154.
   PubMed Web of Science ®Google Scholar
• BANDA NK, VODRACEK A, KRAUS D et al.: Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol (2003) 170:2100–2105.
   PubMed Web of Science ®Google Scholar
• •Evaluation of IL-18BP as a potent inhibitor of CIA induction.
   Google Scholar
• BUFLER P, AZAM T, GAMBONI-ROBERTSON F et al: A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. USA (2002) 99:13723–13728.
   PubMed Web of Science ®Google Scholar
• JOOSTEN LA, VAN DE LOO FA, LUBBERTS E et al: An IFN-y-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. Immunol (2000) 165:6553–6558.
   Web of Science ®Google Scholar
• PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. Glib. Invest. (2001) 108:1825–1832.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: Targeting interleukin 18 with interleukin 18 binding protein. Ann. Rheum. Di t (2000) 59:i17–i20.
   Web of Science ®Google Scholar
• •A thorough review of the efficacy of IL-18BP for experimental RA.
   Google Scholar
• TAKEDA K, TSUTSUI H, YOSHIMOTO T et al.: Defective NK cell activity and TH1 response in IL-18-deficient mice. ImmuniO, (1998) 8:383–390.
   PubMed Web of Science ®Google Scholar
• HOSHINO T, YAGITA H, ORTLDO RH, YOUNG HA: In vivo administration of IL-18 can induce IgE production through TH2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur. Immunol (2000) 30:1998–2006.
   PubMed Web of Science ®Google Scholar
• YOSHIMOTO T, MIZUTANI H, TSUTSUI H et al.: IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat. Immunol (2000) 1:132–137.
   PubMed Web of Science ®Google Scholar
• •Evidence of IL-18 induction of IgE.
   Google Scholar
• KONISHI K, TSUTSUI H, MURAKAMI T et al.: IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc. Natl. Acad. Sci. USA (2002) 99:11340–11345.
   PubMed Web of Science ®Google Scholar
• •Evidence of IL-18-induced AD.
   Google Scholar
• NAKANISHI K: Innate and acquired activation pathways in T cells. Nat. Immunol (2001) 2:140–142.
   PubMed Web of Science ®Google Scholar
• HUNTER CA, TIMANS J, PISACANE P et al.: Comparison of the effects of interleukin-la, interleukin-lp and interferon-y-inducing factor on the production of interferon-y by natural killer. Eur. Immunol (1997) 27:2787–2792.
   PubMed Web of Science ®Google Scholar
• FEHNIGER TA, SHAH MH, TURNER MJ et al.: Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. Immunol. (1999) 162:4511–4520.
   Web of Science ®Google Scholar
• STRENGELL M, MATIKAINEN S, SIREN J et al: IL-21 in synergy with IL-15 or IL-18 enhances IFN-y production in human NK and T cells. I Immunol (2003) 170:5464–5469.
   PubMed Web of Science ®Google Scholar
• FUKAO T, MATSUDA S, KOYASU S: Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-y production by dendritic cells. J. Immunol (2000) 164:64–71.
   PubMed Web of Science ®Google Scholar
• MUNDER M, MALLO M, EICHMANN K, MODOLELL M: Murine macrophages secrete interferon y upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. Exp. Med. (1998) 187:2103–2108.
   PubMed Web of Science ®Google Scholar
• SHIMODA K, TSUTSUI H, AOKI K et al: Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood (2002) 99:2094–2099.
   PubMed Web of Science ®Google Scholar
• PARR MB, PARR EL: The role of y interferon in immune resistance to vaginal infection by herpes simplex virus Type 2 in mice. Virology (1999) 258:282–294.
   PubMed Web of Science ®Google Scholar
• HARANDI AM, SVENNERHOLM B, HOLMGREN J, ERIKSSON K: Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus Type 2 infection in mice but are not required for the development of acquired y interferon-mediated protective immunity. Virol. (2001) 75:6705–6709.
   Web of Science ®Google Scholar
• MORI I, HOSSAIN J, TAKEDA K et al.: Impaired microglial activation in the brain of IL-18-gene-disrupted mice after neurovirulent influenza A virus infection. Virology (2001) 287:163–170.
   PubMed Web of Science ®Google Scholar
• KINJO Y, KAWAKAMI K, UEZU K et al: Contribution of IL-18 to TH1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p40. Immunol. (2002) 169:323–329.
   Web of Science ®Google Scholar
• KAWAKAMI K, KOGUCHI Y, QURESHI MH et al.: IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-y production by NK cells. Immunol (2000) 165:941–947.
   Web of Science ®Google Scholar
• WEI XQ, LEUNG BP, NIEDBALA W et al.: Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J. Immunol. (1999) 163:2821–2828.
   PubMed Web of Science ®Google Scholar
• MONTEFORTE GM, TAKEDA K, RODRIGUEZ-SOSA M et al.: Genetically resistant mice lacking IL-18 gene develop TH1 response and control cutaneous Leishmania major infection. Immunol (2000) 164:5890–5893.
   Web of Science ®Google Scholar
• OHKUSU K, YOSHIMOTO T, TAKEDA K et al.: Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect. Immun. (2000) 68:2449–2456.
   PubMed Web of Science ®Google Scholar
• SINGH RP, KASHIWAMURA S, RAO P et al.: The role of IL-18 in blood-stage immunity against murine malaria Plasmodium yoelii 265 and Plasmodium berghei ANKA. Immunol. (2002) 168:4674–4681.
   Web of Science ®Google Scholar
• OKAMOTO I, KOHNO K, TANIMOTO T, IKEGAMI H, KURIMOTO M: Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. Immunol (1999) 162:3202–3211.
   Web of Science ®Google Scholar
• FUJIMORI Y, YOSHIMOTO T, MATSUI K et al.: Increased expression of interleukin 18 receptor on T lymphocytes in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. j Interferon Cytokine Res. (2002) 22:751–754.
   PubMed Web of Science ®Google Scholar
• OKAMOTO I, KOHNO K, TANIMOTO T et al.: IL-18 prevents the development of chronic graft-versus-host disease in mice../. Immunol. (2000) 164:6067–6074.
   Google Scholar
• TSUTSUI H, NAKANISHI K, MATSUI K et al: Interferon-y-inducing factor upregulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. Immunol. (1996) 157:3967–3973.
   Web of Science ®Google Scholar
• KAYAGAKI N, YAMAGUCHI N, NAKAYAMA M et al.: Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. Immunol. (1999) 162.2639–2647.
   Web of Science ®Google Scholar
• OSAKI T, PERON JM, CAI Q et al.: IFN-y-inducing factor/IL-18 administration mediates IFN-y- and IL-12-independent antitumor effects../. Immunol (1998) 160:1742–1749.
   Google Scholar
• HASHIMOTO W, OSAKI T, OKAMURA H et al.: Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J. Immunol (1999) 163:583–589.
   PubMed Web of Science ®Google Scholar
• OSHIKAWA K, SHI F, RAKHMILEVICH AL et al: Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-113 converting enzyme cDNA. Proc. Natl. Acad. Sci. USA (1999) 96:13351–13356.
   PubMed Web of Science ®Google Scholar
• O'DONNELL MA, LUO Y, CHEN X et al.: Role of IL-12 in the induction and potentiation of IFN-y in response to bacillus Calmette-Guerin. ./. Immunol (1999) 163:4246–4252.
   Google Scholar
• TASAKI K, YOSHIDA Y, MAEDA T et al: Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate Type 1 helper T cells. Cancer Gene Ther (2000) 7:247–254.
   PubMed Web of Science ®Google Scholar
• COUGHLIN CM, SALHANY KE, WYSOCKA M et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. ./. Clin. Invest. (1998) 101:1441–1452.
   Google Scholar
• HOSHINO T, WILTROUT RH, YOUNG HA: IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol (1999) 162:5070–5077.
   PubMed Web of Science ®Google Scholar
• ARMITAGE RJ, FANSLOW WC, STROCKBINE L et al.: Molecular and biological characterization of a murine ligand for CD40. Nature (1992) 357:80–82.
   PubMed Web of Science ®Google Scholar
• HOSHINO T, KAWASE Y, OKAMOTO M et al: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J.Immunol. (2001) 166:7014–7018.
   PubMed Web of Science ®Google Scholar
• KRONENBERG M, GAPIN L: The unconventional lifestyle of NKT cells. Nat. Rev Immunol (2002) 2:557–568.
   PubMed Web of Science ®Google Scholar
• •A current review of NKT cells.
   Google Scholar
• BENDELAC A, RIVERA MN, PARK SH, ROARK JH: Mouse CD1-specific NK1 T cells: development, specificity, and function. AMU. Rev Immunol (1997) 15:535–562.
   PubMed Web of Science ®Google Scholar
• YOSHIMOTO T, PAUL WE: CD4pos,NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. I. Exp. Med. (1994) 179:1285.
   Google Scholar
• LAUW FN, BRANGER J, FLORQUIN S et al.: IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. Immunol (2002) 168:372–378.
   Web of Science ®Google Scholar
• OGURA T, UEDA H, HOSOHARA K et al: Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood(2001) 98:2101–2107.
   PubMed Web of Science ®Google Scholar
• CONTI B, JAHNG JW, TINTI C, SON JH, JOH TH: Induction of interferon-y inducing factor in the adrenal cortex. J. Biol Chem. (1997) 272:2035–2037.
   PubMed Web of Science ®Google Scholar
• KUBOTA T, FANG J, BROWN RA, KRUEGER JM: Interleukin-18 promotes sleep in rabbits and rats. Am. I Physiol Regul Integr Comp. Physiol (2001) 281:R828–R838.
   Web of Science ®Google Scholar
• ROTHE H, JENKINS NA, COPELAND NG, KOLB H: Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. Clin. Invest. (1997) 99:469–474.
   Google Scholar
• WILDBAUM G, YOUSSEF S, GRABIE N, KARIN N: Neutralizing antibodies to IFN-y-inducing factor prevent experimental autoimmune encephalomyelitis. Immunol (1998) 161:6368–6374.
   Web of Science ®Google Scholar
• KANAI T, WATANABE M, AKAZAWA A et al.: Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology (2001) 121:875–888.
   PubMed Web of Science ®Google Scholar
• KANAI T, WATABANE M, OKAZAWA A, SATO T, HIBI T: Interleukin-18 and Crohn's disease. Digestion (2001) 63:37–42.
   PubMed Web of Science ®Google Scholar
• SIVAKUMAR PV, WESTICH GM, KANALY S et al.: Interleukin 18 is a primary mediator of the inflammation associated with dextran sulfate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut (2002) 50:812–820.
   PubMed Web of Science ®Google Scholar
• BALISTRERI WE GRAND R, HOOFNAGLE JH et al.: Biliary atresia: current concepts and research directions. Hepatology (1996) 23:1682–1692.
   Google Scholar
• URUSHIHARA N, IWAGAKI H, YAGI T et aL: Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. Pediatr. Surg. (2000) 35:446–449.
   Google Scholar
• MCGUINNESS PH, PAINTER D, DAVIES S, MCCAUGHAN GW: Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut (2000) 46:260–269.
   PubMed Web of Science ®Google Scholar
• LUDWICZEK O, KASER A, NOVICK D et al.: Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J. Clin. Immunol (2002) 22:331–337.
   PubMed Web of Science ®Google Scholar
• YUMOTO E, HIGASHI T, NOUSO K et al: IL-18 and IL-10 in acute hepatitis: serum y-interferon-inducing factor (IL-18) and IL-18 levels in patients with acute hepatitis and fulminant hepatic failure. Gastroenterol Hepatol (2002) 17:285–294.
   Google Scholar
• VAN DE WATER J, ANSARI AA, SURH CD et al.: Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. Immunol (1991) 146:89–94.
   Google Scholar
• VAN DE WATER J, ANSARI A, PRINDIVILLE T et al.: Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. j Exp. Med. (1995) 181:723–733.
   Google Scholar
• YAMANO T, HIGASHI T, NOUSO K et al.: Serum interferon-y inducing factor/ IL-18 levels in primary biliary cirrhosis. Clin. Exp. Immunol (2000) 122:227–231.
   PubMed Web of Science ®Google Scholar
• YAGI T, IWAGAKI N, URUSHIHARA K et al.: Participation of IL-18 in human cholestatic cirrhosis and acute rejection: analysis in living donor liver transplantation. Transplant. Proc. (2001) 33:421–425.
   PubMed Web of Science ®Google Scholar
• NETEA MG, FANTUZZI G, KULLBERG BJ et al.: Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against Escherichia coil and Salmonella typhimurium endotoxemia. Immunol (2000) 164:2644–2649.
   Web of Science ®Google Scholar
• NAKAMURA H, KOMATSU K, AYAKI M et al.: Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-y in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Allergy Clin. Immunol (2000) 106:45–50.
   Web of Science ®Google Scholar
• FUJIMORI Y, TAKATSUKA H, TAKEMOTO Y et al: Elevated interleukin (ID-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. BE Haematol (2000) 109:652–657.
   PubMed Web of Science ®Google Scholar
• SAKAO Y, TAKEDA K, TSUTSUI H et al: IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int. Immunol (1999) 11:471–480.
   PubMed Web of Science ®Google Scholar
• YOSHIMOTO T, TSUTSUI H, TOMINAGA K et al: IL-18, although anti-allergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl. Acad. Li. USA (1999) 96:13962–13966.
   PubMed Web of Science ®Google Scholar
• TANAKA T, TSUTSUI H, YOSHIMOTO T et aL: Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC/I\Iga. Lit. Arch. Allergy Immunol (2001) 125:236–240.
   PubMed Web of Science ®Google Scholar
• YOSHIZAWA Y, NOMAGUCHI H, IZAKI S, KITAMURA K: Serum cytokine levels in atopic dermatitis. Clin. Exp. Dermatol (2002) 27:225–229.
   PubMed Web of Science ®Google Scholar
• KERR LD: Inflammatory arthritis in the elderly. Mt. Sinaij Med. (2003) 70:23–26.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS: Evolving concepts of rheumatoid arthritis. Nature (2003) 423:356–361.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of RA.
   Google Scholar
• DAVIS LS: The synovial fibroblast in rheumatoid arthritis. Am. Pathol. (2003) 162:1399–1402.
   PubMed Web of Science ®Google Scholar
• WOOLLEY DE: The mast cell in inflammatory arthritis. N Engl. I Med. (2003) 348:1709–1711.
   PubMed Web of Science ®Google Scholar
• •A review of the importance of mast cells for development of CIA.
   Google Scholar
• TAYLOR PC: Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr. Pharm. Des (2003) 9:1095–1106.
   PubMed Web of Science ®Google Scholar
• •A review of anticytokine therapy for RA.
   Google Scholar
• STEINER G, SMOLEN J: Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. (2002) 4:S1–S5.
   Google Scholar
• SILVERMAN GJ, WEISMAN S: Rituximab therapy and autoimmune disorders. Arthritis Rheum. (2003) 48:1484–1492.
   PubMed Web of Science ®Google Scholar
• COURTENAY JS, DALLMAN MJ, DAYAN AD, MARTIN A, MOSEDALE B: Immunization against heterologous Type II collagen induces arthritis in mice. Nature (1980) 283:666–668.
   PubMed Web of Science ®Google Scholar
• •Establishment of CIA.
   Google Scholar
• IWAKURA Y: Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev (2002) 13:341–355.
   PubMed Web of Science ®Google Scholar
• •A thorough review of the contribution of overactivation of IL-1 to the development of RA in mice.
   Google Scholar
• GENTILETTI J, FAVA RA: Does vascular endothelial growth factor play a role in interleukin-6 receptor antagonist therapy for rheumatoid arthritis? Arthritis Rheum. (2003) 48:1471–1474.
   Google Scholar
• •A review of IL-6R antagonist therapy for RA.
   Google Scholar
• ATSUMI T, ISHIHARA K, KAMIMURA D et al.: A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. I Exp. Med. (2002) 196:979–990.
   PubMed Web of Science ®Google Scholar
• •Evaluation of the involvement of abnormal IL-6 signalling in inflammatory arthritis In mice.
   Google Scholar
• WONG PK, CAMPBELL IK, EGAN PJ, ERNST M, WICKS IP: The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum. (2003) 48:1177–1189.
   PubMed Web of Science ®Google Scholar
• SHOUDA T, YOSHIDA T, HANADA T et al.: Induction of the cytokine signal regulator SOCS1/CIS3 as a therapeutic strategy for treating inflammatory arthritis. Clin. Invest. (2001) 108:1781–1788.
   Google Scholar
• •Evaluation of SOCS-3 gene therapy for CIA.
   Google Scholar
• HIRSCHFELD M, KIRSCHNING CJ, SCHWANDNER R et al.: Inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by Toll-like receptor. Immunol (1999) 163:2382–2386.
   Web of Science ®Google Scholar
• CHOE JY, SARAH BC, WU SR, CORR M: Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. Immunol (2003) 197:537–542.
   Google Scholar
• SEIBL R, BIRCHLER T, LOELIGER S et al: Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol (2003) 162:1221–1227.
   PubMed Web of Science ®Google Scholar
• KLINMAN D: Does activation of the innate immune system contribute to the development of rheumatoid arthritis? Arthritis Rheum. (2003) 48:590–593.
   Google Scholar
• LUBBERTS E, JOOSTEN LA, OPPERS B et al: IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. Immunol (2001) 167:1004–1013.
   Web of Science ®Google Scholar
• •Evidence of the importance of endogenous IL-17 for CIA.
   Google Scholar
• HAPPEL KI, ZHENG M, YOUNG E et al.: Roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. Immunol (2003) 170:4432–4436.
   Web of Science ®Google Scholar
• NAKAE S, SAIJO S, HORAI R et al.: IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sri. USA (2003) 100:5986–5990.
   PubMed Web of Science ®Google Scholar
• FOSSIEZ F, DJOSSAU O, CHOMARAT P et al: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. (1996) 183:2593–2603.
   PubMed Web of Science ®Google Scholar
• SCHWARZENBERGER P, LA RUSSA V, MILLER A et aL: IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. Immunol (1998) 161:6383–6389.
   Web of Science ®Google Scholar
• SHALOM-BARAK T, QUANCH J, LOTZE M: Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinase and NF-KB. J. Biol. Chem. (1998) 273:27467–27473.
   PubMed Web of Science ®Google Scholar
• INFANTE-DUARTE C, HORTON HF, BYRNE MC, KAMRADT T: Microbial lipopeptides induce the production of IL-17 in TH cells. Immunol (2000) 165:6107–6115.
   Web of Science ®Google Scholar
• •Demonstration of B. brugdorferi-induced IL-17 production by TH cells.
   Google Scholar
• LINDEN A: Role of interleukin-17 and the neutrophil in asthma. Int. Arch. Allergy Immunol. (2001) 126:179–184.
   PubMed Web of Science ®Google Scholar
• MIOSSEC P: Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. (2003) 48:594–601.
   PubMedGoogle Scholar
• •Review of IL-17 in RA.
   Google Scholar
• JONES HD, KONG YY, PENNINGER JM: Role of RANKL and RANK in bone loss and arthritis. Ann. Rheum. Dis. (2002) 61:ii32-ii39.
   Google Scholar
• ••A thorough review of RANK/RANKL inRA pathology.
   Google Scholar
• SMOLEN JS, GONTER S: Therapeutic strategies for rheumatoid arthritis. Nat. Rev Drug Discov (2003) 2:473–488.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of RA therapy.
   Google Scholar
• TAYLOR PC: Antibody therapy for rheumatoid arthritis. Curr. Opin. Pharmacol (2003) 3:323–328.
   PubMed Web of Science ®Google Scholar
• FELDMANN M: Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev Immunol (2003) 2:364–371.
   Web of Science ®Google Scholar
• ••A thorough review of recent anti-TM'therapy against RA.
   Google Scholar
• MOR L, ISELIN S, DE LIBERO G et al.: Attenuation of collagen-induced arthritis in 55-kDa TNF receptor Type 1 UNFR1)-IgG1 -treated and TNFRI-deficient mice. Immunol 157:3178-3182.
   Google Scholar
• LEE DM, FRIEND DS, GURISH MF et al.: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science (2002) 297:1689–1692.
   PubMed Web of Science ®Google Scholar
• KEANE J, GERSHON S, WISE RP et aL: Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N. Engl. J. Med. (2001) 345:1098–1104.
   PubMed Web of Science ®Google Scholar
• NETEA MG, RADSTAKE T, JOOSTEN LA et al.: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-y production and Toll-like receptor 4 expression. Arthritis Rheum. (2002) 48:1853–1857.
   Google Scholar
• ALONZI T, FATTORI E, LAZZARO D et al.: Interleukin 6 plays a key role in the development of collagen-induced arthritis. Exp. Med. (1998) 187:461–468.
   PubMed Web of Science ®Google Scholar
• ALEXOPOULOU J, THOMAS V, SCHNARE M et al.: Hyporesponsiveness to vaccination with Borrelia burgdoriCri OspA in humans and in TERI- and TER2-deficient mice. Nat. Med. (2002) 8:878–884.
   PubMed Web of Science ®Google Scholar
• •Evidence of the requirement of TLR-mediated signallings for B. burgdorferi products.
   Google Scholar
• PARK CC, MOREL JC, AMIN AM et al.: Evidence of IL-18 as a novel angiogenic mediator. J. Immunol (2000 167:1644–1653.
   Web of Science ®Google Scholar
• •Evaluation of IL-18 as an angiogenic mediator.
   Google Scholar
• GRACIE JA, FORSEY RJ, CHAN WL et al.: A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. (1999) 104:1393–1401.
   PubMed Web of Science ®Google Scholar
• ••First report of the contribution of IL-18to RA pathology.
   Google Scholar
• TANAKA M, HARIGAI M, KAWAGUCHI Y et al.: Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-y production by synovial T cells. J.Rheumatol. (2001) 28:1779–1787.
   PubMed Web of Science ®Google Scholar
• YAMAMURA M, KAWASHIMA M, TANIAI M et al.: Interferon-y-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. (2001) 44:275–285.
   PubMed Web of Science ®Google Scholar
• •Identification of biologically-active IL-18 in the synovial fluid of RA patients.
   Google Scholar
• JOOSTEN LA, RADSTAKE TR, LUBBERTS E et al.: Association of interleukin-18 expression with enhanced levels of both interleukin-lp and tumor necrosis factor a in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. (2003) 48:339–347.
   PubMed Web of Science ®Google Scholar
• •Evaluation of IL-18 as an indicator of disease severity of RA.
   Google Scholar
• BRESNIHAN B, ROUX-LOMBARD P, MURPHY E et al: Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:726–729.
   PubMed Web of Science ®Google Scholar
• MOLLER B, PAULUKAT J, NOLD M et al: Interferon-y induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology (2003) 42:442–445.
   PubMed Web of Science ®Google Scholar
• BYWATERS EGL: Still's disease in the adult. Ann. Rheum. Dis. (1971) 30:121–133.
   PubMed Web of Science ®Google Scholar
• HOSHINO T, OHTA A, YANG D et al.: Elevated serum interleukin 6, interferon-y, and tumor necrosis factor-a levels in patients with adult Still's disease. Rheumatol (1998) 25:396–398.
   Web of Science ®Google Scholar
• KAWASHIMA M, YAMAMURA M, TANIAI M et al.: Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. (2000 44:550–560.
   Google Scholar
• •Evaluation of IL-18 as a possible inducer of ASD.
   Google Scholar
• KAWAGUCHI Y, TERAJIMA H, HARIGAI M, HARA M, KAMATANI N: Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum. (2000 44:1716–1718.
   Google Scholar
• FUJII T, NIJIMA T, YASUOKA H et al: Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (2001) 40:1398–1404.
   Google Scholar
• SUGIURA T, KAWAGUCHI Y, HARIGAI M et al.: Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun. (2002) 3:394–399.
   PubMed Web of Science ®Google Scholar
• SCOLA MP, SHOMPSON SD, BRUNNER HI et al.: Interferon-y.interleukin-4 rations and associated Type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue. Rheumatol. (2002) 29:369–378.
   Google Scholar
• MAENO N, TAKEI S, NOMURA Y et al: Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum. (2002) 46:2539–2541.
   PubMed Web of Science ®Google Scholar
• LE J, VILCEK J: Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab. Invest. (1987) 56:234–248.
   PubMed Web of Science ®Google Scholar
• REBOUL P, PELLETIER JP, TARDIF G, CLOUTIER JM, MARTEL-PELLETIER J: The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: a role in osteoarthritis. Clin. Invest. (1996) 97:2011.
   Google Scholar
• AMIN AR, DAVE M, ATTUR M, ABRAMSON SB: COX-2, NO, and cartilage damage and repair. Curr. RheumatoL Rep. (2000) 2:447–453.
   PubMedGoogle Scholar
• ABRAMSON SB, ATTUR M, AMIN AR, CLANCY R: Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curl: Rheumatol Rep. (2000 3:534–541.
   Google Scholar
• TIVE L: Celecoxib clinical profile. Rheumatology (2000) 39\(Suppl. 2):21–28.
   Google Scholar
• LANAS A: Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology (2002) 41 (Suppl. 1):16–22.
   Google Scholar
• FUTANI H, OKAYAMA A, MATSUI K et al.: Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. .1 Immunother. (2002) 25:S61–S64.
   Google Scholar
• BOILEAU C, MARTEL-PELLETIER J, MOLDOVAN F et al: The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated nitric oxide. Arthritis Rheum. (2002) 46:2637–2647.
   PubMed Web of Science ®Google Scholar
• •A mechanistic approach to experimental OA focusing on caspase-1/IL–18.
   Google Scholar
• COUSSENS LM, WERB Z: Inflammation and cancer. Nature (2002) 420:860–867.
   PubMed Web of Science ®Google Scholar
• •A review of the role of inflammatory chemokines in angiogenesis during tumour growth.
   Google Scholar
• BUCKLEY CD: Why do leucocytes accumulate within chronically inflamed joints? Rheumatology (2003) 42:1–12.
   Google Scholar
• KOCH AE, KUNKEL SL, HARLOW LA et al.: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis.j Clin. Invest. (1992) 90:772–779.
   Google Scholar
• SNOWDEN N, HAJEER A, THOMSON W, OLLIER B: RANTES role in rheumatoid arthritis. Lancet (1994) 343:547–548.
   PubMed Web of Science ®Google Scholar
• ALAAEDDINE N, OLEE T, HASHIMOTO S, CREIGHTON-ACHERMANN L, LOTZE M: Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum (2001) 44:1633–1643.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI Y, ICHIJO Y, NAGATAKE H et al.: Processing of interleukin-lp in synovial cells freshly isolated from patients with rheumatoid arthritis. Biochem. Biophys. Res. Commun. (1994) 199:1035–1040.
   PubMed Web of Science ®Google Scholar
• KAWASHIMA M, MIOSSEC P: Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum. (2003) 48:631–637.
   PubMedGoogle Scholar
• •Identification of IL-18R expression in RA synovial cells.
   Google Scholar
• MOLLER B, KUKOC-ZIVOJNOV N, KESSLER U et al.: Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. Rheumatology (2001) 40:302–309.
   PubMed Web of Science ®Google Scholar
• LEUNG BP, CULSHAW S, GRACIE JA et al.: A role for IL-18 in neutrophil activation. J. Immunol (2001) 167:2879–2886.
   PubMed Web of Science ®Google Scholar
• LEUNG BP, MCINNES TB, ESFANDIARI E, WET XQ, LIEW FY: Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. Immunol (2000) 164:6495–6502.
   Web of Science ®Google Scholar
• •Evaluation of exogenous IL-18 as an exacerbation factor in CIA.
   Google Scholar
• MOREL JC, PARK CC, KUMAR P, KOCH AE: Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NF-KB activation. Lab. Invest. (2001) 81:1371–1383.
   PubMed Web of Science ®Google Scholar
• RUTH JH, SHAHRARA S, PARK CC et al.: Role of macrophage inflammatory protein-3a and its ligand CCR6 in rheumatoid arthritis. Lab. Invest. (2003) 83:579–588.
   PubMed Web of Science ®Google Scholar
• MOREL JC, PARK CC, WOODS JM, KOCH AE: A novel role for interleukin-18 in adhesion molecule induction through NF-KB and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J. Biol Chem. (2001) 276:37069–37075.
   PubMed Web of Science ®Google Scholar
• MOREL JC, PARK CC, ZHU K et al.: Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast IL-18-induced vascular cell adhesion molecule-1 expression../. Biol. Chem. (2002) 277:34679–34691.
   Google Scholar
• PFEILSCHIFTER J, KODITZ R, PFOHL M, SCHATZ H: Changes in proinflammatory cytokine activity after menopause. Endocr. Rev (2002) 23:90–119.
   PubMed Web of Science ®Google Scholar
• •A thorough review of roles of pro-inflammatory cytokines in postmenopausal bone loss.
   Google Scholar
• LAM J, TAKESHITA S, BARKER JE et al.: TNF-a induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. Clin. Invest. (2000) 106:1481–1488.
   Google Scholar
• ••Evaluation of endogenous TNF-a togetherwith RANKL in osteoclastogenesis.
   Google Scholar
• CENCI S, TORALDO G, WEITZMANN MN et al.: Estrogen deficiency induces bone loss by increasing T cell proliferation and life span through IFN-y-induced Class II transactivater. Proc. Nati Acad. Sci. USA (2003) 100:10405–10410.
   PubMed Web of Science ®Google Scholar
• •Evaluation of endogenous IL-18 in oestrogen deficiency-induced bone loss.
   Google Scholar
• ROGGIA C, GAO Y, CENCI S et al.: Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA (2001) 98:13960–13965.
   PubMed Web of Science ®Google Scholar
• HORWOOD NJ, ELLIOTT J, MARTIN TJ et al: IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro." Immunol. (2001) 166:4915–4921.
   PubMed Web of Science ®Google Scholar
• YAMADA N, NIWA S, TSUJIMURA T et al.: Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone (2002) 30:901–908.
   PubMed Web of Science ®Google Scholar
• MAKIISHI-SHIMOBAYASHI C, SHUJIMURA T, IWASAKI T et al.: Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem. Biophys. Res. Commun. (2001) 281:361–366.
   PubMed Web of Science ®Google Scholar
• KAWASE T, HOSHINO T, YOKOTA K et al: Bone malformations in interleukin-18 transgenic mice. J. Bone Miner. Res. (2003) 18:975–983.
   PubMed Web of Science ®Google Scholar
• TAKAYANAGI H, OGASAWARA K, HIDA S et al: T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-y. Nature (2000) 406:600–605.
   PubMedGoogle Scholar
• WET X, LEUNG BP, ARTHUR HM, MCINNES TB, LIEW FY: Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J. Immunol (2001) 166:517–521.
   PubMed Web of Science ®Google Scholar
• •Evaluation of endogenous IL-18 for Induction of CIA pathology.
   Google Scholar
• SMEETS RL, VAN DE LOO FAJ, ARNTZ OJ et al.: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. (2003) 10:1004–1011.
   Google Scholar
• •Evaluation of IL-18BP gene therapy for CIA.
   Google Scholar
• KOBAYASHI K, HERNANDEZ LD, GALAN JE et al.: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 110:191–202.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA R, NAKA T, TSUTSUI H et al.: SOCS-1 participates in negative regulation of LPS response. Immunity (2002) 17:677–687.
   PubMed Web of Science ®Google Scholar
• KINJYO I, HANADA T, INAGAKI-OHARA K et al: SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity (2002) 17:583–591.
   PubMed Web of Science ®Google Scholar
• WALD D, QIN J, ZHAO Z et al: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. (2003) 4:920–927.
   PubMed Web of Science ®Google Scholar
• MCINNES TB, LEUNG BP, STURROCK RD, FIELD M, LIEW FY: Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-a production in rheumatoid arthritis. Nat. Med. (1997) 2:189–195.
   Google Scholar
• KIM WU, MIN SY, CHO ML et al.: The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis. Clin. Exp. Immunol. (2000) 119:175–181.
   PubMed Web of Science ®Google Scholar
• CORDERO OJ, SALGADO FJ, MERA-VARELA A, NOGUEIRA M: Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int. (2001) 21:69–74.
   PubMed Web of Science ®Google Scholar
• MCINNES TB, AL-MUCHALES J, FIELD M et al.: The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. (1996) 2:175–182.
   PubMed Web of Science ®Google Scholar
• SHAH MH, HACKSHAW KV, CALIGIURI MA: A role for IL-15 in rheumatoid arthritis? Nat. Med. (1998) 4:643.
   Web of Science ®Google Scholar
• KUROWSKA M, RUNDNICKA W, KONTNY E et al.: Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bc1-XL and Bc1-2. J.Immunol. (2002) 169:1760–1767.
   PubMed Web of Science ®Google Scholar
• MCINNES TB, LIEW FY: Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today (1998) 19:75–79.
   PubMedGoogle Scholar
• ••A review of the importance of IL-15 inRA pathology.
   Google Scholar
• DAYER JM: Interleukin-18, rheumatoid arthritis, and tissue destruction. Clin. Invest. (1999) 104:1337–1339.
   Google Scholar
• MCINNES TB, GRACIE JA, LIEW FY: Interleukin-18: a novel cytokine in inflammatory rheumatic disease. Arthritis Rheum. (2001) 44:1481–1483.
   PubMedGoogle Scholar
• LIEW FY, MCINNES TB: Role of interleukin 15 and interleukin 18 in inflammatory response. Ann. Rheum. Dis. (2002) 61:ii100-ii102.
   Google Scholar
• LILE CW, KIENER PA, LEDBETTER JA, ARUFFO A, KLEBANOFF SJ: Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med (1996) 184:429–440.
   PubMed Web of Science ®Google Scholar
• OHASHI K, BURKART V, FLOHE S, KOLB H: Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex../. Immunol (2000) 164:558–561.
   PubMed Web of Science ®Google Scholar
• DYBDAHL B, ZAHBA A, LIEN E et al.: Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through Toll-like receptor-4. Circulation (2002) 105:685–690.
   PubMed Web of Science ®Google Scholar
• VABULAS RM, AHMAD-NEJAD P, GHOSE S et al.: HSP70 as endogenous stimulus of the Toll-Interleukin-1 receptor signal pathway. J. Biol. Chem. (2002) 277:15107–15112.
   PubMed Web of Science ®Google Scholar
• VABULAS RM, WAGNER H, SCHILD H: Heat shock proteins as ligands of Toll-like receptors. Curl: Top. Microbial. Immunol (2002) 270:169–184.
   PubMed Web of Science ®Google Scholar
• SCHETT G, TOHIDAST-AKRAD M, STEINER G, SMOLEN J: The stressed synovium. Arthritis Res. (2001) 3:80–86.
   PubMedGoogle Scholar
• SHARIF M, WORRALL JG, SINGH G et al.: The development of monoclonal antibodies to the human mitochondrial 60-kD heat-shock protein, and their use in studying the expression of the protein in rheumatoid arthritis. Arthritis Rheum. (1992) 35:1427–1433.
   PubMed Web of Science ®Google Scholar
• •Identification of HSP60 in RA tissues.
   Google Scholar
• SCHETT G, REDLICH K, XU Q et al: Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue.j Clia Invest (1998) 102:302–311.
   PubMed Web of Science ®Google Scholar
• •Identification of HSP70 in RA tissues.
   Google Scholar
• PITTONI V, BOMBARDIERI M, SPINELLI FR et al.: Anti-tumor necrosis factor (TNF) a treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (ID-18 but not IL-12 and IL-13. Ann. Rheum. DR (2002) 61:723–725.
   PubMed Web of Science ®Google Scholar
• •Clinical data of IL-18 reduction after treatment of RA with anti-TNF-a treatment.
   Google Scholar